Robert Chess Sells 3,600 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 3,600 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $47.26, for a total value of $170,136.00. Following the completion of the transaction, the director now directly owns 21,641 shares of the company’s stock, valued at $1,022,753.66. The trade was a 14.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $38.96 on Friday. The stock’s 50-day simple moving average is $43.90 and its two-hundred day simple moving average is $45.88. Twist Bioscience Co. has a twelve month low of $18.80 and a twelve month high of $60.90.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on TWST shares. JPMorgan Chase & Co. raised their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Robert W. Baird increased their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Barclays lowered their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Leerink Partners increased their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $51.22.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC grew its stake in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. grew its stake in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience in the second quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.